Objectives: To determine the effect of vasopressin therapy on the efficacy of oxygenation and arterial pressure in infants with severe persistent pulmonary hypertension of the newborn. Conclusions ...

But pulmonary hypertension still persists. "There's amelioration, improved survival, but no cure," says Kourembanas, chief of the Division of Newborn Medicine at Boston Children's Hospital.

exerts a rapid pulmonary vasodilatation and is an established treatment of pulmonary hypertension (PH) in newborn infants (3). iNO has, however, several disadvantages, such as unpredictable and ...

The identified trials included 625 children, with more than 140 infants. Persistent pulmonary hypertension of the newborn and pulmonary hypertension associated with other conditions were the most ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension.

Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary artery denervation (PADN) as an innovative intervention for ...

lost their newborn Eden Rose after being born with severe primary pulmonary hypertension at a regional hospital. The hospital lacked both the training and equipment to diagnose and treat Eden.

"Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis" has shed light on the potential of pulmonary artery denervation (PADN) as an innovative intervention for ...